Latest news with #AdvaMed
Yahoo
2 days ago
- Business
- Yahoo
Medtech leaders unite on Capitol Hill to fight tariffs
Amid ongoing trade policy debates, leaders from the medtech industry convened on Capitol Hill alongside the Advanced Medical Technology Association (AdvaMed) to advocate for the elimination of tariffs on medical technologies. Senior executives from medtech giants including GE HealthCare, Roche Diagnostics, and Karl Storz participated in the June 11 initiative, signaling a unified industry stance on key policy priorities. In a LinkedIn post spotlighting the advocacy efforts in Washington, D.C., Roland Rott, President & CEO of Imaging at GE HealthCare, called for policy reforms that spur innovation and expand access to care. Highlighting the need for actionable change, Rott stated that healthcare must remain a strategic priority 'not just in rhetoric, but through meaningful policy decisions.' Rott was joined by prominent industry leaders, including Peter Arduini, CEO of GE HealthCare; Brad Moore, CEO of Roche Diagnostics North America; Sonal Matai, US leader at Karl Storz; John Kowal, head of Siemens Healthineers Americas; Scott Whitaker, CEO of AdvaMed; and Roxy Kozycky, Senior Director at AdvaMed. The leaders called for several core policy changes: "zero for zero" tariffs on medical technologies, modernised reimbursement models that include AI innovations, and strong protections for public research funding and global scientific collaboration. The recommendations come amid significant concern from the US medtech industry over President Trump's recent tariff policies, particularly those targeting imports from China, Canada, and Mexico. Industry leaders have warned that the tariffs could disrupt supply chains, increase costs, and hinder innovation. In the near term, the full impact of US government tariffs on the medtech sector remains uncertain. GlobalData analysis indicates that healthcare facilities may begin to stock up on medical devices to prepare for increased pricing. Manufacturers such as Medtronic have adopted a strategic approach and expanded their US-based production to reduce any negative impact on their financial outlook. Analysts speculate that if the tariffs can be supported by pro-manufacturing policies, they could encourage the re-shoring of medtech production and potentially drive new investments in US-based supply chains and startups. "Medtech leaders unite on Capitol Hill to fight tariffs" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
10-05-2025
- Business
- Yahoo
Why Boston Scientific Corporation (BSX) Is Among the Best Medical Device Stocks to Buy Now
We recently published a list of . In this article, we are going to take a look at where Boston Scientific Corporation (NYSE:BSX) stands against other best medical device stocks to buy now. On April 16, CNBC reported that Trump's tariffs are building a divide in the medical community. The first Trump administration did not impose tariffs on medical devices and protective gear manufactured in Mexico, China, and Canada. However, the sector has not received a reprieve from the president's newest round of duties so far. This has resulted in a division: since device makers could potentially face significant challenges from tariffs, they are pushing back for a way out. In contrast, personal protective equipment manufacturers stand to benefit from the barriers created by the levies, which is why they are not showing signs of a push back. The medical community is thus presenting a dichotomy in the face of tariffs. CNBC reported that the duties could also raise costs for hospitals, and in turn, patients, ultimately reducing access to critical care and equipment. Scott Whitaker, CEO of AdvaMed, the trade group representing medical technology and device makers, said the following about the situation: 'MedTech supply chain leaders are already reporting supply chain concerns, and we cannot afford to drive up the cost of health care for patients, or on the health care system. The reality is, any increased costs will be largely borne by taxpayer-funded health programs like Medicare, Medicaid, and the VA.' Hospital trade groups are also voicing their concerns, warning that tariffs could bring the quality of care down. CNBC reported that Rick Pollack, the CEO of the American Hospital Association, opined: 'The AHA has and will continue to share with the Administration, disruptions in the availability of these critical devices — many of which are sourced internationally — have the potential to disrupt patient care. AHA continues to push for a tariff exemption for medical devices to ensure that hospitals and health systems can continue to serve their patients and communities.' READ ALSO: Recession Resistant Investing: 10 Best Grocery Stocks To Buy Now and 11 Most Promising Future Stocks According to Hedge Funds. President Trump imposed a 25% tariff on imported goods from Mexico and Canada in February, later delaying levies on a number of items falling under the US-Mexico-Canada Agreement. However, Chinese goods have not seen any reprieve. In fact, the new levies imposed in Trump's second term have brought the total tariff rate up to 145%. While a way out of the present conditions is to raise prices to offset the rising expenses from tariffs, a range of hospitals and other organizations buying medical equipment cannot do so. These institutions are thus likely to face complications passing on higher costs under the current insurance coverage contracts with locked-in yearly prices. Casey Hite, CEO of Aeroflow Health, a firm that provides insurance-covered medical devices, said the following: 'With the level of tariffs that we're looking at in China, businesses are going to be completely upside down on these products … they can't pass those costs on to the consumer. I think what we would like to see, more than anything, is a runway or some predictability. Let's do this over the next 12 months, next two years, so that US organizations can prepare.' We sifted through stock screeners, financial media reports, and ETFs to compile a list of 25 best medical device stocks and then chose the top 11 with the highest number of hedge fund holders as of Q4 2024. We sourced the hedge fund sentiment data from Insider Monkey's database. The list is ordered in ascending order of hedge fund sentiment. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 363.5% since May 2014, beating its benchmark by 208 percentage points (). A surgeon examining a patient's brain in an operating room, paramedics nearby. Number of Hedge Fund Holders: 96 Boston Scientific Corporation (NYSE:BSX) manufactures, develops, and markets medical devices used in interventional medical procedures. Its operations are divided into Cardiovascular and MedSurg segments. The Cardiovascular segment covers Cardiology and Peripheral Interventions, while the MedSurg segment comprises Urology, Endoscopy, and Neuromodulation. The company ranks fourth on our list of the top medical device stocks to invest in. On April 25, Barclays analyst Matt Miksic raised the firm's price target on Boston Scientific Corporation (NYSE:BSX) to $125 from $118, keeping an Overweight rating on the shares. The firm reasoned that solid results from ADVANTAGE-AF for using Farawave and Farapoint in persistent atrial fibrillation should allow FDA approval later this year. BTIG analyst Marie Thibault also maintained their bullish stance on the stock on April 23, giving it a buy rating based on its solid financial performance and promising outlook. Boston Scientific Corporation (NYSE:BSX) reported notable fiscal Q1 2025 revenue and EPS, surpassing both market expectations and its own guidance. The analyst attributed this success to higher-than-expected sales in electrophysiology and interventional cardiology. This holds especially true for the Farapulse franchise, which has positioned the company as a leader in the electrophysiology market. Boston Scientific Corporation (NYSE:BSX) has raised its 2025 revenue guidance, and the upcoming CFO transition is expected to maintain stability in leadership, reflecting confidence in its stable growth and sustained profitability. Overall, BSX ranks 4th on our list of the best medical device stocks to buy now. While we acknowledge the potential for BSX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than BSX but trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
10-05-2025
- Business
- Yahoo
Zimmer Biomet Holdings, Inc. (ZBH): Among the Best Medical Device Stocks to Buy Now
We recently published a list of . In this article, we are going to take a look at where Zimmer Biomet Holdings, Inc. (NYSE:ZBH) stands against other best medical device stocks to buy now. On April 16, CNBC reported that Trump's tariffs are building a divide in the medical community. The first Trump administration did not impose tariffs on medical devices and protective gear manufactured in Mexico, China, and Canada. However, the sector has not received a reprieve from the president's newest round of duties so far. This has resulted in a division: since device makers could potentially face significant challenges from tariffs, they are pushing back for a way out. In contrast, personal protective equipment manufacturers stand to benefit from the barriers created by the levies, which is why they are not showing signs of a push back. The medical community is thus presenting a dichotomy in the face of tariffs. CNBC reported that the duties could also raise costs for hospitals, and in turn, patients, ultimately reducing access to critical care and equipment. Scott Whitaker, CEO of AdvaMed, the trade group representing medical technology and device makers, said the following about the situation: 'MedTech supply chain leaders are already reporting supply chain concerns, and we cannot afford to drive up the cost of health care for patients, or on the health care system. The reality is, any increased costs will be largely borne by taxpayer-funded health programs like Medicare, Medicaid, and the VA.' Hospital trade groups are also voicing their concerns, warning that tariffs could bring the quality of care down. CNBC reported that Rick Pollack, the CEO of the American Hospital Association, opined: 'The AHA has and will continue to share with the Administration, disruptions in the availability of these critical devices — many of which are sourced internationally — have the potential to disrupt patient care. AHA continues to push for a tariff exemption for medical devices to ensure that hospitals and health systems can continue to serve their patients and communities.' READ ALSO: Recession Resistant Investing: 10 Best Grocery Stocks To Buy Now and 11 Most Promising Future Stocks According to Hedge Funds. President Trump imposed a 25% tariff on imported goods from Mexico and Canada in February, later delaying levies on a number of items falling under the US-Mexico-Canada Agreement. However, Chinese goods have not seen any reprieve. In fact, the new levies imposed in Trump's second term have brought the total tariff rate up to 145%. While a way out of the present conditions is to raise prices to offset the rising expenses from tariffs, a range of hospitals and other organizations buying medical equipment cannot do so. These institutions are thus likely to face complications passing on higher costs under the current insurance coverage contracts with locked-in yearly prices. Casey Hite, CEO of Aeroflow Health, a firm that provides insurance-covered medical devices, said the following: 'With the level of tariffs that we're looking at in China, businesses are going to be completely upside down on these products … they can't pass those costs on to the consumer. I think what we would like to see, more than anything, is a runway or some predictability. Let's do this over the next 12 months, next two years, so that US organizations can prepare.' We sifted through stock screeners, financial media reports, and ETFs to compile a list of 25 best medical device stocks and then chose the top 11 with the highest number of hedge fund holders as of Q4 2024. We sourced the hedge fund sentiment data from Insider Monkey's database. The list is ordered in ascending order of hedge fund sentiment. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 363.5% since May 2014, beating its benchmark by 208 percentage points (). A team of medical specialists discussing orthopaedic reconstructive surgery plans. Number of Hedge Fund Holders: 53 Zimmer Biomet Holdings, Inc. (NYSE:ZBH) designs, manufactures, and markets orthopedic reconstructive products. It also offers biologics, extremities, sports medicine, dental implants, trauma products, and related surgical products. The company leads the orthopedic sector with a 36% share in knee implants and a 23% share in hip implants. Zimmer Biomet Holdings, Inc. (NYSE:ZBH) also holds a competitive market advantage due to its regulatory expertise, as the development of medical implants requires a lengthy FDA approval process, creating a natural barrier to entry and limiting competition. On April 25, BTIG analyst Ryan Zimmerman maintained a Buy rating on Zimmer Biomet Holdings, Inc. (NYSE:ZBH) and set a price target of $123.00. The analyst said that the company's recent strategic product introductions in the hip replacement sector position it well to regain market share. The company has launched innovative products such as the Z1 Triple Taper Stem, HAMMR, and OrthoGrid, which have received generally optimistic feedback from orthopedic surgeons. The products can improve Zimmer Biomet Holdings, Inc.'s (NYSE:ZBH) competitive position, supporting the Buy rating. Overall, ZBH ranks 11th on our list of the best medical device stocks to buy now. While we acknowledge the potential for ZBH as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than ZBH but trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
10-05-2025
- Business
- Yahoo
Why Thermo Fisher Scientific Inc. (TMO) is Among the Best Medical Device Stocks to Buy Now
We recently published a list of . In this article, we are going to take a look at where Thermo Fisher Scientific Inc. (NYSE:TMO) stands against other best medical device stocks to buy now. On April 16, CNBC reported that Trump's tariffs are building a divide in the medical community. The first Trump administration did not impose tariffs on medical devices and protective gear manufactured in Mexico, China, and Canada. However, the sector has not received a reprieve from the president's newest round of duties so far. This has resulted in a division: since device makers could potentially face significant challenges from tariffs, they are pushing back for a way out. In contrast, personal protective equipment manufacturers stand to benefit from the barriers created by the levies, which is why they are not showing signs of a push back. The medical community is thus presenting a dichotomy in the face of tariffs. CNBC reported that the duties could also raise costs for hospitals, and in turn, patients, ultimately reducing access to critical care and equipment. Scott Whitaker, CEO of AdvaMed, the trade group representing medical technology and device makers, said the following about the situation: 'MedTech supply chain leaders are already reporting supply chain concerns, and we cannot afford to drive up the cost of health care for patients, or on the health care system. The reality is, any increased costs will be largely borne by taxpayer-funded health programs like Medicare, Medicaid, and the VA.' Hospital trade groups are also voicing their concerns, warning that tariffs could bring the quality of care down. CNBC reported that Rick Pollack, the CEO of the American Hospital Association, opined: 'The AHA has and will continue to share with the Administration, disruptions in the availability of these critical devices — many of which are sourced internationally — have the potential to disrupt patient care. AHA continues to push for a tariff exemption for medical devices to ensure that hospitals and health systems can continue to serve their patients and communities.' READ ALSO: Recession Resistant Investing: 10 Best Grocery Stocks To Buy Now and 11 Most Promising Future Stocks According to Hedge Funds. President Trump imposed a 25% tariff on imported goods from Mexico and Canada in February, later delaying levies on a number of items falling under the US-Mexico-Canada Agreement. However, Chinese goods have not seen any reprieve. In fact, the new levies imposed in Trump's second term have brought the total tariff rate up to 145%. While a way out of the present conditions is to raise prices to offset the rising expenses from tariffs, a range of hospitals and other organizations buying medical equipment cannot do so. These institutions are thus likely to face complications passing on higher costs under the current insurance coverage contracts with locked-in yearly prices. Casey Hite, CEO of Aeroflow Health, a firm that provides insurance-covered medical devices, said the following: 'With the level of tariffs that we're looking at in China, businesses are going to be completely upside down on these products … they can't pass those costs on to the consumer. I think what we would like to see, more than anything, is a runway or some predictability. Let's do this over the next 12 months, next two years, so that US organizations can prepare.' We sifted through stock screeners, financial media reports, and ETFs to compile a list of 25 best medical device stocks and then chose the top 11 with the highest number of hedge fund holders as of Q4 2024. We sourced the hedge fund sentiment data from Insider Monkey's database. The list is ordered in ascending order of hedge fund sentiment. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 363.5% since May 2014, beating its benchmark by 208 percentage points (). A workstation in a research lab stocked with laboratory products and services. Number of Hedge Fund Holders: 100 Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the best medical device stocks to buy now. It provides analytical instruments, reagents, equipment, and other services for analysis, research, diagnostics, and discovery. It operates through the Analytical Instruments, Life Sciences Solutions, Laboratory Products and Services, and Specialty Diagnostics segments. In a report released on April 25, Jill Wu from CMB International Securities maintained a Buy rating on Thermo Fisher Scientific Inc. (NYSE:TMO) and set a price target of $526.00. The analyst supported this rating with the company's ability to effectively manage macroeconomic challenges despite experiencing headwinds such as US domestic policy changes and tariffs. Thermo Fisher Scientific Inc. (NYSE:TMO) also surpassed adjusted EPS and revenue expectations in fiscal Q1 2025, which suggests strong and stable demand in most of its business segments, especially the biotech and pharma markets. The company plans to invest $2 billion in the coming four years to expand its R&D facilities and US manufacturing, highlighting its commitment to long-term growth. Overall, TMO ranks 2nd on our list of the best medical device stocks to buy now. While we acknowledge the potential for TMO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than TMO but trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10-05-2025
- Business
- Yahoo
Is DexCom, Inc. (DXCM) the Best Medical Device Stock to Buy Now?
We recently published a list of . In this article, we are going to take a look at where DexCom, Inc. (NASDAQ:DXCM) stands against other best medical device stocks to buy now. On April 16, CNBC reported that Trump's tariffs are building a divide in the medical community. The first Trump administration did not impose tariffs on medical devices and protective gear manufactured in Mexico, China, and Canada. However, the sector has not received a reprieve from the president's newest round of duties so far. This has resulted in a division: since device makers could potentially face significant challenges from tariffs, they are pushing back for a way out. In contrast, personal protective equipment manufacturers stand to benefit from the barriers created by the levies, which is why they are not showing signs of a push back. The medical community is thus presenting a dichotomy in the face of tariffs. CNBC reported that the duties could also raise costs for hospitals, and in turn, patients, ultimately reducing access to critical care and equipment. Scott Whitaker, CEO of AdvaMed, the trade group representing medical technology and device makers, said the following about the situation: 'MedTech supply chain leaders are already reporting supply chain concerns, and we cannot afford to drive up the cost of health care for patients, or on the health care system. The reality is, any increased costs will be largely borne by taxpayer-funded health programs like Medicare, Medicaid, and the VA.' Hospital trade groups are also voicing their concerns, warning that tariffs could bring the quality of care down. CNBC reported that Rick Pollack, the CEO of the American Hospital Association, opined: 'The AHA has and will continue to share with the Administration, disruptions in the availability of these critical devices — many of which are sourced internationally — have the potential to disrupt patient care. AHA continues to push for a tariff exemption for medical devices to ensure that hospitals and health systems can continue to serve their patients and communities.' READ ALSO: Recession Resistant Investing: 10 Best Grocery Stocks To Buy Now and 11 Most Promising Future Stocks According to Hedge Funds. President Trump imposed a 25% tariff on imported goods from Mexico and Canada in February, later delaying levies on a number of items falling under the US-Mexico-Canada Agreement. However, Chinese goods have not seen any reprieve. In fact, the new levies imposed in Trump's second term have brought the total tariff rate up to 145%. While a way out of the present conditions is to raise prices to offset the rising expenses from tariffs, a range of hospitals and other organizations buying medical equipment cannot do so. These institutions are thus likely to face complications passing on higher costs under the current insurance coverage contracts with locked-in yearly prices. Casey Hite, CEO of Aeroflow Health, a firm that provides insurance-covered medical devices, said the following: 'With the level of tariffs that we're looking at in China, businesses are going to be completely upside down on these products … they can't pass those costs on to the consumer. I think what we would like to see, more than anything, is a runway or some predictability. Let's do this over the next 12 months, next two years, so that US organizations can prepare.' We sifted through stock screeners, financial media reports, and ETFs to compile a list of 25 best medical device stocks and then chose the top 11 with the highest number of hedge fund holders as of Q4 2024. We sourced the hedge fund sentiment data from Insider Monkey's database. The list is ordered in ascending order of hedge fund sentiment. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 363.5% since May 2014, beating its benchmark by 208 percentage points (). A doctor demonstrating how to use the medical device to a patient with diabetes. Number of Hedge Fund Holders: 69 DexCom, Inc. (NASDAQ:DXCM) is a medical device company that manufactures continuous glucose monitoring (CGM) systems to allow real-time health management control. Specializing in diabetes care technology, the company is the seventh best medical device stock to buy now. It offers various medical devices and products, including Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. On May 5, Analyst Mike Kratky from Leerink Partners reiterated a Buy rating on DexCom, Inc. (NASDAQ:DXCM). He increased the price target to $101.00 from $95.00, based on the company's impressive fiscal Q1 2025 sales that surpassed consensus estimates. The growth was driven by a notable increase in new customer starts in the US market. While the company is facing some challenges like increased inventory replenishment costs affecting gross margins, management is optimistic about overcoming these expenses through operational efficiencies. The analyst views DexCom, Inc.'s (NASDAQ:DXCM) unchanged full-year sales guidance as conservative, given the various growth drivers. These include recovery in the durable medical equipment share, increased coverage for Type 2 patients, and the expected uptake of the G7 sensor. Overall, DXCM ranks 7th on our list of the best medical device stocks to buy now. While we acknowledge the potential for DXCM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than DXCM but trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
